由于没有对身体畸形障碍进行筛查,澳洲化妆品行业面临检查。 Aussie cosmetic industry faces scrutiny over lack of screenings for body dysmorphic disorder.

澳大利亚化妆品业价值40亿美元,缺乏对身体畸形障碍(BDD)的适当筛查,这一疾病影响到多达20%的化妆品患者。 The Australian cosmetic industry, worth $4 billion, lacks proper screenings for body dysmorphic disorder (BDD), a condition affecting up to 20% of cosmetic patients. 由于远程保健而导致工业快速增长,经过长达60秒的短暂磋商,引起了对患者脆弱性的关切。 Rapid industry growth due to telehealth, with some consultations as brief as 60 seconds, raises concerns about patient vulnerability. 医生和其他开业医生,如护士,可能面临新的条例,规定在程序前必须进行业连评估。 Doctors and other practitioners like nurses may face new regulations requiring BDD assessments before procedures. 专家建议,需要更多监督,以保护病人免受不必要的治疗。 Experts suggest more oversight is needed to protect patients from unnecessary treatments.